In this special issue of DCAT Value Chain Insights, we are providing information that would have been presented at the DCAT Member Company Announcement Forum at DCAT Week ’20. Originally scheduled to be held on March 23 in New York, these announcements were selected by the Announcement Oversight Task Force, as they present the latest major company news impacting the pharmaceutical manufacturing value chain. CEOs and senior executives from DCAT member companies outline their companies’ growth strategies by providing updates on key mergers and acquisitions and expansions with news from the following companies: Cambrex, Recipharm, Thermo Fisher Scientific, Lonza, SK pharmteco, Catalent, Biocon, CordenPharma, and WuXi STA. The individual news developments are outlined below.

• Cambrex CEO Outlines Company’s Growth Strategy

• Recipharm Begins Integration of $629-M Acquisition of Consort Medical

• Thermo Fisher Investing $475 M to Expand Capacity and Capabilities

• Lonza Updates Plan for New Mammalian Biomanufacturing Facility in China

• SK pharmteco Launches Newly Formed CDMO

• Catalent Adds Cell/Gene-Therapy Services with $315-M Buy of MaSTherCell

• Biocon Investing $100 M in New Fermentation-Based API Mfg Facility

• CordenPharma Adds Commercial Aseptic Fill–Finish Capacity and R&D Lab

• WuXi STA Expands Oligo, HPAPI and Peptide Manufacturing in China